A 52-year-old postmenopausal woman with newly diagnosed hormone receptor-positive (HR+), HER2-negative breast cancer presents for treatment planning. She has no prior history of thromboembolic disease or endometrial pathology. What is the drug of choice for first-line endocrine therapy in this patient?

Explanation

## First-Line Endocrine Therapy in Postmenopausal HR+ Breast Cancer ### Mechanism of Action Aromatase inhibitors (AIs) block the enzyme aromatase, which converts androgens to estrogen in postmenopausal women. This is the preferred mechanism in the postmenopausal setting because estrogen production occurs primarily in adipose tissue and other peripheral sites, not the ovaries. ### Why Aromatase Inhibitors Are First-Line **Key Point:** In postmenopausal women with HR+ breast cancer, aromatase inhibitors (letrozole, anastrozole, or exemestane) are preferred over tamoxifen as first-line endocrine therapy [cite:Harrison 21e Ch 397]. **High-Yield:** Multiple landmark trials (ATAC, BIG 1-98, TEAM) demonstrate superior disease-free survival and lower rates of endometrial cancer and thromboembolic events with AIs compared to tamoxifen in the postmenopausal population. ### Comparison of First-Line Options | Agent | Setting | Mechanism | Advantage | Disadvantage | |-------|---------|-----------|-----------|---------------| | **Aromatase Inhibitor** | Postmenopausal (1st-line) | Blocks peripheral estrogen synthesis | Superior DFS, fewer thromboembolic events, no endometrial risk | Bone loss, arthralgias | | Tamoxifen | Premenopausal or postmenopausal (alternative) | Selective estrogen receptor modulator | Protective bone effect, can be used premenopausal | Thromboembolic risk, endometrial cancer risk | | Fulvestrant | Advanced disease (2nd/3rd-line) | Estrogen receptor degrader | Useful after AI resistance | Requires IM injection, slower onset | | GnRH agonist | Premenopausal (adjunct) | Ovarian suppression | Renders premenopausal women postmenopausal | Not monotherapy for postmenopausal women | ### Clinical Pearl Postmenopausal status is defined as ≥5 years since last menstrual period, age >60, or FSH in postmenopausal range. In this patient, an AI (letrozole 2.5 mg or anastrozole 1 mg daily) is the standard of care for adjuvant or metastatic HR+ disease. ### Bone Health Consideration **Tip:** Patients on long-term AI therapy require baseline DEXA scan and calcium/vitamin D supplementation to mitigate bone loss and fracture risk.